Scottish Health Innovations Ltd (SHIL) works in partnership with NHS Scotland to identify, protect, develop and commercialise new innovations from healthcare professionals. Registered Number: SC 236303. Registered address: The Golden Jubliee National Hospital, Fourth Floor East, Agmemmon St, Clydebank, G81 4DY
Coronex was set up in April 2020 to address unmet needs in Lateral Flow (LF) antibody testing. It has brought together experts in the development of large scale test and antigen manufacture. Partners in the Coronex collaboration are Scottish Health Innovations Ltd (representing NHS Greater Glasgow & Clyde), together with a number of Scottish and UK based biotechnology industry partners – Excivion Ltd, Lateral Dx Ltd, Activotec Ltd, The Antibody Company Ltd - and Glasgow based investment partner Axon Healthcare Investments Ltd.
Coronex’s technological advancements optimise antibody detection, while minimising non-specific background binding and allow the target antigen to be easily changed. This means the test kits are cheaper to manufacture, easily altered to adapt to virus mutations and give clearer, more accurate results. The technology has been developed and tested over six months on a cohort of COVID-19 samples provided by the NHS Greater Glasgow and Clyde Biorepository Network.
“An expert team has been mobilised at speed and we are now supporting a rapid, robust process to create a prototype, test against clinical samples; and if successful, progress through regulatory approval to manufacture. We are working at pace; but must remain cognisant that we are innovating at speed within a healthcare setting and with evolving scientific evidence.”
“I am so proud of our team of clinicians, research nurses, biorepository specialists and patients who have made it possible to kick-start the development of a brand new antibody test for COVID-19. This is part of our wider research and development efforts to improve the diagnosis and treatment of the virus which includes clinical trials and innovative projects and the wider R&D Team.